To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy

Phase 2， randomized, open lable, multi-center, active controlled study. Patients are randomized to Genakumab 200mg single injection group or Etoricorxib 120mg qd po.(until remission or intorlerance, no longer than 8 days) group.

1. Male or female, 18 years ≤ age ≤ 75 years;
2. BMI ≤ 40kg/m2
3. Meeting ACR 2015 preliminary criteria for the classification of acute arthritis of primary gout;
4. Start of acute gout flare within 3 days prior to enrolled;
5. History of ≥2 gout flare within 12 months prior to study start;
6. Baseline pain intensity ≥ 50mm on the 0-100mm visual analog scale(VAS)